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PRECLINICAL STUDY
rythropoietin Enhances Neovascularization of
schemic Myocardium and Improves Left Ventricular
ysfunction After Myocardial Infarction in Dogs
kio Hirata, MD,* Tetsuo Minamino, MD, PHD,* Hiroshi Asanuma, MD, PHD,* Masashi Fujita, MD,*
asakatsu Wakeno, MD,† Masafumi Myoishi, MD,† Osamu Tsukamoto, MD,* Ken-ichiro Okada, MD,*
idekazu Koyama, BS,* Kazuo Komamura, MD, PHD,§ Seiji Takashima, MD, PHD,*
oshiro Shinozaki, MD, Hidezo Mori, MD, PHD,§ Masamichi Shiraga, MD, PHD,‡
asafumi Kitakaze, MD, PHD, FACC,§ Masatsugu Hori, MD, PHD, FACC*
saka and Kanagawa, Japan
OBJECTIVES We investigated the effects of erythropoietin (EPO) on neovascularization and cardiac
function after myocardial infarction (MI).
BACKGROUND Erythropoietin exerts antiapoptotic effects and mobilizes endothelial progenitor cells (EPCs).
METHODS We intravenously administered EPO (1,000 IU/kg) immediately [EPO(0) group], 6 h
[EPO(6h) group], or 1 week [EPO(1wk) group] after the permanent ligation of the coronary
artery in dogs. Control animals received saline immediately after the ligation.
RESULTS The infarct size 6 h after MI was significantly smaller in the EPO(0) group than in the control
group (61.5  6.0% vs. 22.9  2.2%). One week after MI, the circulating CD34-positive
mononuclear cell numbers in both the EPO(0) and the EPO(6h) groups were significantly
higher than in the control group. In the ischemic region, the capillary density and
myocardial blood flow 4 weeks after MI was significantly higher in both the EPO(0) and
the EPO(6h) groups than in the control group. Four weeks after MI, left ventricular (LV)
ejection fraction in the EPO(6h) (48.6  1.9%) group was significantly higher than that
in either the control (41.9  0.9%) or the EPO(1wk) (42.6  1.2%) group but
significantly lower than that in the EPO(0) group (56.1  2.3%). The LV end-diastolic
pressure 4 weeks after MI in both the EPO(0) and the EPO(6h) groups was significantly lower
than either the control or the EPO(1wk) group. Hematologic parameters did not differ among the
groups.
CONCLUSIONS In addition to its acute infarct size-limiting effect, EPO enhances neovascularization, likely
via EPC mobilization, and improves cardiac dysfunction in the chronic phase, although it has
time-window limitations. (J Am Coll Cardiol 2006;48:176–84) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.008College of Cardiology Foundation
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0rythropoietin (EPO) is a cytokine that promotes prolifer-
tion and differentiation of erythroid precursor cells (1) and
s widely used for the treatment of anemia in patients with
hronic renal failure (2). Erythropoietin can also exert
ntiapoptotic and radical scavenger effects on nonerythroid
ells (3,4). Indeed, we and others showed that an adminis-
ration of EPO before or shortly after the onset of ischemia
See page 185
educed myocardial infarct size and improved cardiac func-
ion in acute phases (5–8). Another interesting nonery-
hroid function of EPO is the promotion of endothelial
rogenitor cell (EPC) mobilization in animals and humans
From the Departments of *Cardiovascular Medicine, †Bioregulatory Medicine, and
Hematology and Oncology, Osaka University Graduate School of Medicine, Suita,
saka, Japan; §Cardiovascular Division of Internal Medicine, National Cardiovas-
ular Center, Suita, Osaka, Japan; and the Department of Physiological Science,
okai University School of Medicine, Isehara, Kanagawa, Japan.o
Manuscript received June 14, 2005; revised manuscript received November 10,
005, accepted November 30, 2005.9–11), which may enhance neovascularization of ischemic
reas (12,13). We hypothesized that EPO increases blood
upply to ischemic regions through promoting neovascular-
zation and improves cardiac dysfunction after ischemic
nsult. Thus, the goal of this study was to characterize the
ffects of EPO on neovascularization and cardiac function
fter myocardial infarction (MI) in the chronic phase.
ETHODS
ll procedures were performed in conformity with the Guide
or the Care and Use of Laboratory Animals (NIH publication
o. 85-23, 1996 revision) and were approved by the Osaka
niversity Committee for Laboratory Animal Use.
nstrumentation. Forty-seven beagle dogs (Kitayama
abes, Yoshiki Farm Gifu, Japan), weighing 8 to 12 kg were
sed in these experiments. After an intravenous injection of
odium pentobarbital (15 mg/kg), the dogs were intubated
nd ventilated. General anesthesia was maintained with
.5% to 2.0% inhaled isoflurane. After baseline echocardi-
graphy and hemodynamic assessment, minimal thoracot-
o
c
d
d
a
(
d
E
C
I
(
t
a
w
R
m
E
(
E
E
s
i
[
n
s
a
H
r
t
e
p
C
t
l
M
T
r
Q
c
w
b
p
t
w
fl
D
F
a
177JACC Vol. 48, No. 1, 2006 Hirata et al.
July 4, 2006:176–84 EPO Enhances Neovascularization After MImy was performed, and then the left anterior descending
oronary artery (LAD) was ligated just distal to the first
iagonal branch. To ensure that all animals included in the
ata analysis were exposed to a similar extent of ischemia,
nimals with excessive myocardial collateral blood flow
15 ml/100 g/min) were excluded from study as previously
escribed (14).
xperimental protocols. ACUTE EFFECTS OF EPO ON MYO-
ARDIAL INFARCT SIZE. Either a single dose of EPO (1,000
U/kg; 5 ml) (n  6) or the same volume of saline
n  6) was administered intravenously immediately after
he LAD ligation. Regional myocardial blood flow (MBF),
rea at risk, and infarct size at 6 h after the LAD ligation
ere determined as described previously (Fig. 1) (14).
Abbreviations and Acronyms
ABP  arterial mean blood pressure
Dil-ac-LDL  1,1=-dioctadecyl-3,3,3=,3=-
tetramethylindocarbocyanine-labeled
acetylated low density lipoprotein
EPC  endothelial progenitor cell
EPO  erythropoietin
HR  heart rate
LAD  left anterior descending coronary artery
LCX  left circumflex coronary artery
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic dimension
LVEDP  left ventricular end-diastolic pressure
MBF  myocardial blood flow
MI  myocardial infarction
MNC  mononuclear cell
UEA-I  Ulex europaeus agglutinin I
VEGF  vascular endothelial growth factorigure 1. Experimental protocols to investigate acute effects of erythropoietin (E
rtery; RhEPO  recombinant human erythropoietin.ecombinant human EPO was provided by Chugai Phar-
aceutical Co. Ltd. (Tokyo, Japan). Recombinant human
PO is effective for correcting anemia in the beagle dog
15).
FFECTS OF IMMEDIATE OR DELAYED TREATMENT WITH
PO ON NEOVASCULARIZATION AND CARDIAC FUNCTION. A
ingle dose of EPO (1,000 IU/kg; 5 ml) was administered
ntravenously immediately [EPO(0) group, n  8], 6 h
EPO(6h) group, n  8], or 1 week [EPO(1wk) group,
 7] after the LAD ligation. Control animals received the
ame volume of saline (control group, n  8) immediately
fter the LAD ligation.
ematologic parameters. Blood was sampled from a pe-
ipheral vein under pentobarbital (15 mg/kg) anesthesia at
he time points indicated in Figure 2. Hematologic param-
ters, including hematocrit, white blood cell count, and
latelet count, were measured.
ytokine measurements. Plasma levels of vascular endo-
helial growth factor (VEGF) were measured by enzyme-
inked immunosorbent assay (R & D Systems, Minneapolis,
innesota). The detection limit of the assays was 9 pg/ml.
he reliability of this assay in dogs has already been
eported previously (16).
uantification of CD34-positive mononuclear cells. The
irculating CD34-positive mononuclear cells (CD34MNCs)
ere quantified at the time points indicated in Figure 2. In
rief, peripheral white blood cells were stained with a
hycoerythrin-conjugated anticanine CD34 monoclonal an-
ibody (BD Pharmingen, San Diego, California). Samples
ere then subjected to a two-dimensional side-scatter-
uorescence dot plot analysis (FACScan, Becton-
ickinson, Tokyo, Japan). After appropriate gating ofPO) on myocardial infarct size. LAD  left anterior descending coronary
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EPO Enhances Neovascularization After MI July 4, 2006:176–84NCs, the number of CD34MNCs with low cytoplas-
ic granularity (low sideward scatter) was quantified and
xpressed as the number of cells per 1-l blood sample.
n vitro MNC culture assay. Circulating MNCs were
solated from blood (10 ml) of dogs at baseline and 1 week
fter MI in the control and EPO(0) groups (n  4 each) by
icoll density-gradient centrifugation. After MNCs (107
er well) were plated in Medium 199 (Gibco, Grand Island,
ew York) supplemented with 20% fetal calf serum and
ntibiotics on human fibronectin-coated six-well dishes.
fter 7 days in culture, adherent cells were stained for the
ptake of 1,1=-dioctadecyl-3,3,3=,3=-tetramethylindo-
arbocyanine-labeled acetylated low-density lipoprotein (DiI-
c-LDL) (Biomedical Technologies, Stoughton, Massachu-
etts) and the binding of fluorescein isothiocyanate-labeled
lex europaeus agglutinin I (UEA-I) (Vector Laboratories,
eterborough, England). Double-staining cells were quantified
y examining five random microscopic fields (200 power)
10,11).
istologic assessments. Four weeks after MI, myocardial
issue was sampled from both ischemic (LAD) and non-
schemic (left circumflex coronary artery [LCX]) regions in
ach group. The tissues in the ischemic region were iden-
ified as the edge of the region showing necrosis. These
amples were then fixed in 10% buffered formalin, embed-
ed in paraffin, and serially sectioned in the frontal plane at
-m thickness. Endothelial cells were immunohistologi-
ally stained using rabbit antihuman von Willebrand factor
ntibody (Dako, Kyoto, Japan) and the Envision/HRP
it (Dako) (17). The peroxidase was visualized by incuba-
ion with 3,3'-diaminobenzidine, followed by incubation
ith a DAB-enhancing solution (Dako). We counted the
igure 2. Experimental protocols to investigate effects of immediate or d
unction. CD34MNC  CD34-positive mononuclear cell; other abbrevumbers of capillaries and cardiomyocytes in 20 random tigh-power fields (400 power), and then calculated the
verage capillary density and capillary-to-myocyte ratio
18).
easurements of regional MBF. Regional MBF was
etermined as described previously (19). Nonradioactive
icrospheres (Sekisui Plastic Co., Tokyo, Japan) made of
nert plastic were labeled with bromine or niobium.
icrospheres were administered at 90 min and 4 weeks
fter MI. The MBF in the LAD region was calculated
ccording to the following formula: time flow (tissue count)
(reference flow)/(reference count), and was expressed in
l/g wet weight/min.
emodynamic measurements. Hemodynamic parameters,
uch as arterial mean blood pressure (ABP), heart rate (HR),
nd left ventricular end-diastolic pressure (LVEDP), were
easured at the time points indicated in Figure 2. A 5-F
idearm sheath (Radifocus, Terumo, Tokyo, Japan) was placed
n the right femoral artery for hemodynamic measurements. A
-F pigtail catheter (Outlook, Terumo) was placed in the LV
or measurement of LVEDP and was connected to a pressure
ransducer (model DX-200, Nihon Kohden, Tokyo, Japan).
he ABP and HR were monitored via the 5-F sidearm sheath.
chocardiography. Cardiac function was assessed by echo-
ardiography (Sonos 5500, S4-probe, 2-4 MHz, Philips,
othell, Washington) at the time points indicated in Figure 2.
hort-axis views were recorded at the level of midpapillary
uscles, and two-dimensional and M-mode views were
ecorded at the same level. Measurements of left ventricular
nd-diastolic dimension (LVEDD) and LV ejection frac-
ion were obtained from M-mode views. All measurements
ere made by one observer, who was blinded with respect to
treatment with erythropoietin (EPO) on neovascularization and cardiac
s as in Figure 1.he identity of the tracings.
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July 4, 2006:176–84 EPO Enhances Neovascularization After MInfarct size 4 weeks after MI. Myocardial infarct area was
etermined at the end of the protocol by triphenyltetrazo-
ium chloride staining as described previously (14). Infarct
ize was expressed as a percentage of the total LV area.
tatistical analysis. Results are expressed as the mean 
tandard error of the mean. Comparisons of the time course
f the change between groups were performed using two-
ay repeated measures analysis of variance. Comparisons of
ther data between groups were performed using one-way
actional analysis of variance. If statistical significance was
ound for a group, a time effect, or a group-by-time interaction,
urther comparisons were made with paired t tests between all
ossible pairs of four groups at individual time points. The
onferroni-Holm procedure was used for correction of
ultiple comparisons. A p value 0.05 was considered to
epresent statistical significance (20).
ESULTS
xclusion. Four dogs [acute effects protocol; control: 1,
PO: 0, delayed treatment effects protocol; control: 1,
PO(0): 1, EPO(6h): 0, EPO(1wk): 1] were excluded from
igure 3. Representative left ventricular cross sections at 6 h after myoca
reatment. (C) Infarct size at 6 h after MI. *p  0.05 vs. the control grou
able 1. Time Course of Changes in Hematologic Parameters
Parameters Baseline 1 Week 2 Weeks 4 Weeks
ematocrit (%)
Control 52.9  1.7 47.0  1.6 48.9  2.3 53.1  1.8
EPO(0) 52.4  1.1 48.2  1.2 47.9  1.4 53.4  0.7
EPO(6h) 51.5  1.6 49.3  1.6 51.4  1.1 51.3  2.3
EPO(1wk) 48.9  1.0 46.4  1.1 49.4  0.5 50.1  1.0
BC (103/l)
Control 13.8  0.4 15.4  1.4 15.3  0.9 13.5  0.9
EPO(0) 12.6  0.6 14.0  1.1 14.4  0.3 12.3  1.4
EPO(6h) 12.6  0.8 15.6  1.1 13.9  1.0 12.0  0.8
EPO(1wk) 13.1  0.8 14.8  1.2 13.3  0.4 12.9  0.8
latelet (104/mm3)
Control 27.3  2.0 26.5  1.9 28.4  1.2 26.2  2.0
EPO(0) 28.5  2.0 26.8  4.3 27.0  3.4 28.2  1.8
EPO(6h) 26.9  0.9 27.0  1.4 26.1  1.8 26.1  1.5ata are presented as mean  SEM (n  7 to 8).
EPO  erythropoietin; WBC  white blood cell.
Dnalysis because of excessive regional MBF (15 ml/100
/min). Thus, 12 and 31 dogs in acute and delayed EPO
reatment protocols, respectively, were included.
cute effects of EPO on infarct size. Myocardial infarct
ize was significantly smaller in animals receiving EPO com-
ared with those that received saline, but there was no
ignificant difference in regional MBF (9.0  1.0 ml/100
/min vs. 8.5 1.2 ml/100 g/min) or area at risk (42.9 2.3%
s. 42.3  0.9%) when comparing the two groups (Fig. 3).
ffects of EPO on hematologic parameters. The average
hange in hematologic parameters was not different when
omparing the three EPO-treated groups and the control
roup over the 4-week experimental protocol (Table 1).
lasma VEGF levels. Table 2 shows the time course of
hanges in plasma VEGF level after MI. The plasma
EGF level was significantly and comparably elevated in
oth control and EPO(0) groups, peaking on 6 h after MI,
nd returned to baseline at 1 week after MI.
irculating CD34MNCs and in vitro cultured MNCs.
igure 4A shows the time course of changes in circulating
D34MNC number in the different groups. One week
fter MI, the number of circulating CD34MNCs in-
reased in all groups. Furthermore, the number of circulat-
ng CD34MNCs at 1 week after MI was higher in the
PO(0) and EPO(6h) groups than in either control or
PO(1wk) group. Two weeks after MI, the number of
D34MNCs in the control group returned to the base-
ine. By contrast, the number of CD34MNCs in the
PO(0) and EPO(6h) groups also decreased but still
emained higher than those in either the control or
infarction (MI) in dogs with (B) and without (A) erythropoietin (EPO)
pen circles  infarct size in each animal.
able 2. Time Course of Changes in Plasma VEGF Levels
Groups n Baseline 6 Hours 1 Week 2 Weeks
EGF (pg/ml)
Control 4 9.0 22.5  3.3* 9.0 9.0
EPO(0) 4 9.0 21.6  5.0* 9.0 9.0ata are presented as mean  SEM. *p  0.05 vs. baseline.
EPO  erythropoietin; VEGF  vascular endothelial growth factor.
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EPO Enhances Neovascularization After MI July 4, 2006:176–84PO(1wk) group. Furthermore, the administration of EPO
week after the LAD ligation did not affect the number of
D34MNCs at any given time point.
In the culture assay of MNCs, the number of Dil-ac-
DL/UEA-I double-positive cells obtained from blood 1
eek after MI increased compared with that at baseline in
oth control and EPO(0) groups. Importantly, the double-
ositive cell number obtained from blood 1 week after MI in
he EPO(0) group was significantly higher than in the
ontrol group (Figs. 4B and 4C).
apillary density and regional MBF. Figure 5A shows
he representative immunohistologic findings in the non-
schemic (panels a to d) and ischemic (panels e to h) regions
t 4 weeks after MI. In the nonischemic region, there was
o difference in the capillary density and capillary-to-
yocyte ratio when comparing groups. In the ischemic
egion, the capillary-to-myocyte ratio as well as capillary
ensity was significantly higher in the EPO(0) and
PO(6h) groups, but not in the EPO(1wk) group, than in
he control group (Figs. 5B to 5C).
Figure 6 shows the changes in regional MBF in the
schemic regions in different experimental groups. There
as no significant difference in MBF at 90 min when
igure 4. (A) Time course of changes in circulating CD34MNC cou
xperimental groups. (B) Representative images of double-stained cultured
ow density lipoprotein [Dil-ac-LDL] and Ulex europaeus agglutinin I [UE
nd without erythropoietin (EPO) treatment immediately after LAD ligat
.05 vs. the control group. †p  0.05 vs. baseline.omparing experimental groups. At 4 weeks after MI, gBF was more increased in the EPO(0) and EPO(6h)
roups, but not in the EPO(1wk) group, than in the
ontrol group.
ffects of immediate or delayed EPO treatment on cardiac
unction and infarct size. Throughout the experimental
rotocols, there was no difference in either ABP or HR
hen comparing the groups (Table 3).
Figure 7 shows the time course of changes in LVEF
panel A), LVEDD (panel B), and LVEDP (panel C) in
ifferent experimental groups. There were no significant
ifferences in baseline LVEF, LVEDD, and LVEDP when
omparing the groups.
Ninety minutes, 1 week, and 4 weeks after MI, LVEF
as higher in the EPO(0) group than in the other groups.
inety minutes and 1 week after MI, there was no differ-
nce in LVEF when comparing the EPO(6h) group and the
ontrol group. When comparing the time points of 1 week
nd 4 weeks after MI, LVEF decreased in the control and
he EPO(1wk) groups but not in the EPO(6h) group. One
nd 4 weeks after MI, LVEDD was lower in the EPO(0)
roup than in the other groups. When comparing the time
oints of 1 week and 4 weeks after MI, LVEDD increased
n the control and EPO(1wk) groups but not in the EPO(6h)
ter left anterior descending coronary artery (LAD) ligation in different
1,1=-dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-labeled acetylated
) at baseline (a, b) and 1 week after LAD ligation (c, d) from dogs with
C) Quantitative analysis of endothelial progenitor cell culture assay. *p nt af
cells (
A-I]roup. Ninety minutes after MI, LVEDP was lower in the
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July 4, 2006:176–84 EPO Enhances Neovascularization After MIPO(0) group than in the other groups. Four weeks after MI,
VEDP was lower in the EPO(0) and EPO(6h) groups than
n either the control or the EPO(1wk) group.
Myocardial infarct size 4 weeks after MI was smaller in
he EPO(0) group than in the control group, although EPO
reatment, initiated 6 h and 1 week after MI, did not reduce
nfarct size (Fig. 7D).
ISCUSSION
he present study showed that EPO administered 6 h after
AD ligation increased circulating CD34MNCs, capil-
ary density, MBF in the ischemic region, and prevented
he worsening of cardiac function without reducing
nfarct size. The EPO enhances neovascularization, likely
ia EPC mobilization, and improves cardiac dysfunction
n the chronic phase, although EPO has time-window
imitations.
We showed that the EPO treatment immediately after
he LAD ligation reduced infarct size, which is consistent
ith observations of previous reports (5–8). Because the
nfarct size-limiting effects of EPO appear rapidly, the
onerythroid effects of EPO, such as antiapoptosis and
adical scavenging (4–8), may contribute to the reduction of
igure 5. (A) Representative immunohistologic staining with an antibody
LCX]) (a, b, c, d) and ischemic (left anterior descending coronary artery
B) and capillary-to-myocyte ratio (C) of nonischemic (LCX) and ischemi
roup. Abbreviations as in Figure 1.nfarct size. iRecent reports have shown that circulating CD34MNC
ount correlated with EPC number in MNCs culture assay,
nd both increased at 1 to 2 weeks after EPO administration
n animals and humans (9–11). In the culture assay, the
umber of Dil-ac-LDL/UEA-I double-positive cells ob-
ained from blood at baseline did not differ between the two
roups. The number of double-positive cells obtained from
lood at 1 week after MI significantly increased compared
ith that at baseline in the control and EPO(0) groups.
urther, the double-positive cell number obtained from
lood in the EPO(0) group was higher than in the control
roup. These findings suggest that EPO augments increases
n the number of MNCs that can differentiate into Dil-ac-
DL/UEA-I double-positive cells, an indicator of endothe-
ial cells. Increases in the number of both CD34-positive
ells and Dil-ac-LDL/UEA-I double-positive cells strongly
uggest that EPO promotes EPC mobilization. The num-
er of CD34MNCs increased 1 week after MI in the
anine model, which is consistent with observations from
tudies of patients with acute MI (21,22). Furthermore, the
umber of CD34MNCs was higher in the EPO(0) and
PO(6h) groups than in the control group. This finding
uggests that a single dose of EPO was effective in increas-
st von Willebrand factor in nonischemic (left circumflex coronary artery
]) (e, f, g, h) regions in different experimental groups. Capillary density
D) regions in different experimental groups. *p  0.05 versus the controlagain
[LADng the number of circulating EPCs after MI. Interestingly,
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EPO Enhances Neovascularization After MI July 4, 2006:176–84PO administered 1 week after MI failed to produce the
dentical effect, suggesting that EPO has a time window for
romotion of EPC mobilization. We found that plasma
EGF levels were elevated, peaking at 6 h after MI and
eturned to the baseline 1 week after MI. The EPO did not
ffect plasma VEGF levels. Because both VEGF and EPO
re known to promote EPC mobilization in experimental
onditions and are independent predictors for the number of
irculating EPCs in patients with coronary heart disease
9–11,23), they may additionally or synergistically contrib-
te to EPC mobilization. Thus, it is likely that EPO alone,
t least at the dose used in the present study, might not be
nough to promote CD34MNC mobilization 1 week
fter MI when VEGF returns to the baseline. Although we
nly investigated the low dose of EPO to consider the
linical implication, it is possible that high doses of EPO
ould show the different results. Further investigations are
eeded to clarify the mechanism of EPO-stimulated EPC
obilization.
The present study also showed that EPO increased
apillary-to-myocyte ratio corrected for LV hypertrophy
s well as capillary density in the EPO(0) and EPO(6h)
roups, suggesting that EPO promotes the neovasculariza-
ion in the ischemic region. Investigators have also reported
hat EPO enhances neovascularization in the ischemic
egion in the hind-limb occlusion model (9). As suggested
n the present study, EPO may enhance neovascularization
ia EPC mobilization. Indeed, bone marrow-derived EPCs
ncorporate into foci of neovascularization at the border
one of MI (12,13), and administration of ex vivo-expanded
PCs resulted in increased myocardial neovascularization
24,25). In a rat stroke model, Wang et al. (26) showed that
PO treatment, initiated 24 h after MI, enhances angio-
enesis. In addition, van der Meer et al. (27) showed that
apillary density was increased in the rat post-MI model even
igure 6. Regional myocardial blood flow in the ischemic (left anterior
escending coronary artery [LAD]) region 90 min and 4 weeks afterfl
yocardial infarction in different experimental groups. *p 0.05 versus the
ontrol group. EPO  erythropoietin.hen EPO was administered 3 weeks after MI. In contrast, we
howed that EPO administered 1 week after MI failed to
ncrease capillary density. The possible explanation for this
iscrepancy is attributable to the different doses of EPO
sed. In the studies by Wang et al. (26) (5,000 IU/kg for 7
ays) and van der Meer et al. (27) (8,000 IU/kg every 3
eeks), relatively high doses of EPO were administered. In
ontrast, in the present study, a relatively low dose (1,000
U/kg) of EPO was administered with a single injection,
nd the reason for this dose in the present study is for the
ossible translation of our results to clinical settings more
asily (6), because 8,000 or 5,000 IU/kg EPO may cause
ide effects. On the other hand, we noticed that a higher
ose of EPO would increase capillary density and improve
he cardiac function even by the late administration of EPO
or clinical use.
In the present study, MBF in the ischemic region was
ncreased in both the EPO(0) and the EPO(6h) groups.
ecause neovascularization was also enhanced in these
roups, increased MBF may occur secondary to the en-
anced neovascularization.
The present study also showed that an administration of
PO immediately after the LAD ligation improved cardiac
unction at 90 min after MI, likely because of infarct size
eduction, and subsequently prevented the development of
ardiac dysfunction in the chronic phase. Because the
revious reports showed that myocardial necrosis progresses
ithin 6 h after the onset of MI (28,29), EPO was
dministered at time points of 6 h and later after LAD
igation to determine whether its activity is directed toward
he acute phase of MI or the chronic phase of cardiac
ysfunction. One week after MI, LVEF, LVEDD, or
VEDP was similar among the EPO(6h), EPO(1wk),
nd control groups. However, EPO administered 6 h, but
ot 1 week, after the LAD ligation improved cardiac
ysfunction 4 weeks after MI when compared with the
ontrol group. Because we did not find any difference in
nfarct size at 4 weeks after MI between the EPO(6h)
nd the EPO(1wk) groups, the improvement of cardiac
unction in the EPO(6h) group was not attributable to
he reduction of infarct size, but to the increased blood
able 3. Time Course of Changes in Hemodynamic Parameters
Parameters Baseline 90 Min 4 Weeks
BP (mm Hg)
Control 99  3 101  3 103  2
EPO(0) 102  3 99  3 102  2
EPO(6h) 101  1 98  2 101  1
EPO(1wk) 102  2 102  3 103  2
R (per min)
Control 131  6 135  6 129  6
EPO(0) 128  6 131  3 131  5
EPO(6h) 130  7 135  7 126  6
EPO(1wk) 128  6 128  3 126  6
ata are presented as mean  SEM (n  7 to 8).
ABP  arterial mean blood pressure; EPO  erythropoietin; HR  heart rate.ow to the ischemic regions.
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ize reduction, EPO may exert chronic cardioprotective
ffects through neovascularization and may be a useful
djunct for the treatment of patients with myocardial
nfarction.
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